KELOWNA, BC / ACCESS Newswire / January 30, 2025 / Lexaria Bioscience Corp. , (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to provide this annual letter from ...

A/S, a global healthcare company specializing in diabetes care and other chronic conditions, has been at the forefront of the rapidly expanding GLP-1 market. With a market capitalization of $376.79 ...

Scholar Rock submitted its BLA of apitegromab for the treatment of patients with Spinal Muscular Atrophy with a request for ...

Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $724 billion, has been ...

Surgical patients may still have leftovers in their system even after a standard fast, potentially increasing the chance of a serious complication.

Lexaria Bioscience (LEXX) provided an annual letter from CEO Richard Christopher, which read in part, “In 2024, Lexaria made the course ...

With new drug development, a significant increase in sales, and high potential with Mounjaro and Zepbound, here’s what we think of Eli Lilly’s stock ...